Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias.
Cognitive Disorders
Creutzfeldt-Jakob
Dementia
Neurofilament
Neurogranin
Prion disease
SNAP-25
Synapses
Tau
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
10
03
2023
accepted:
27
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14-3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240-1250 vs. 115, 95% CI 78-157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411-1473 vs. 390, 95% CI 260-766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873-0.931) exceeded that of 14-3-3 (AUC 0.853, 95% CI 0.816-0.889), t-tau (AUC 0.878, 95% CI 0.845-0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851-0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626-0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593-0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729-0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40-2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21-2.93). In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14-3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14-3-3 and NfL, respectively.
Sections du résumé
BACKGROUND
The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia.
METHODS
In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14-3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses.
RESULTS
CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240-1250 vs. 115, 95% CI 78-157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411-1473 vs. 390, 95% CI 260-766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873-0.931) exceeded that of 14-3-3 (AUC 0.853, 95% CI 0.816-0.889), t-tau (AUC 0.878, 95% CI 0.845-0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851-0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626-0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593-0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729-0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40-2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21-2.93).
CONCLUSIONS
In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14-3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14-3-3 and NfL, respectively.
Identifiants
pubmed: 37684653
doi: 10.1186/s13195-023-01300-y
pii: 10.1186/s13195-023-01300-y
pmc: PMC10485978
doi:
Substances chimiques
Neurogranin
132654-77-4
Synaptosomal-Associated Protein 25
0
Prions
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1181-1188
pubmed: 32928934
PLoS One. 2013 Jun 26;8(6):e68062
pubmed: 23840812
Acta Neuropathol. 2021 Oct;142(4):707-728
pubmed: 34324063
Cerebellum. 2002 Jul;1(3):213-22
pubmed: 12879983
Neuroreport. 1993 Jan;4(1):65-8
pubmed: 8453038
JAMA Neurol. 2019 Aug 01;76(8):969-977
pubmed: 31058916
J Neurol. 2019 Dec;266(12):3136-3143
pubmed: 31541342
J Neurosci. 2007 Jun 6;27(23):6224-33
pubmed: 17553995
Neuropathol Appl Neurobiol. 2015 Aug;41(5):631-45
pubmed: 25134744
Brain Commun. 2022 Aug 02;4(4):fcac201
pubmed: 35974795
Handb Clin Neurol. 2018;153:155-174
pubmed: 29887134
J Alzheimers Dis. 2017;55(4):1471-1480
pubmed: 27886009
Acta Neuropathol. 2017 Apr;133(4):559-578
pubmed: 28205010
Alzheimers Res Ther. 2018 Jan 11;10(1):3
pubmed: 29368621
Alzheimers Res Ther. 2022 Oct 12;14(1):153
pubmed: 36221099
J Neurol Neurosurg Psychiatry. 2022 Aug 22;:
pubmed: 35995553
Mol Neurobiol. 2017 Sep;54(7):5177-5191
pubmed: 27562179
Neurobiol Dis. 1999 Apr;6(2):92-100
pubmed: 10343324
Ann Neurol. 1999 Aug;46(2):224-33
pubmed: 10443888
Mol Cell Neurosci. 2019 Jun;97:81-92
pubmed: 30529227
Acta Neuropathol. 2009 Nov;118(5):659-71
pubmed: 19718500
Ann Clin Transl Neurol. 2016 Dec 27;4(2):139-144
pubmed: 28168213
Brain Pathol. 2019 Mar;29(2):278-300
pubmed: 30588685
Ann Neurol. 2012 Aug;72(2):278-85
pubmed: 22926858
J Alzheimers Dis. 2018;64(4):1051-1065
pubmed: 30010123
Alzheimers Dement. 2020 Feb;16(2):262-272
pubmed: 31668967
Expert Rev Proteomics. 2020 Jul - Aug;17(7-8):543-559
pubmed: 33028119
Acta Neuropathol Commun. 2020 Jul 25;8(1):117
pubmed: 32711575
Neurobiol Aging. 2021 Dec;108:99-109
pubmed: 34551375
Nat Med. 2011 Feb;17(2):175-8
pubmed: 21278748
Alzheimers Dement (Amst). 2021 Jun 29;13(1):e12214
pubmed: 34222611
Neurology. 2021 May 18;96(20):e2546-e2557
pubmed: 33795390
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853
pubmed: 31097472
J Neurol. 2007 Jul;254(7):901-6
pubmed: 17385081
Lancet Neurol. 2021 Mar;20(3):235-246
pubmed: 33609480
Alzheimers Dement. 2020 Oct;16(10):1438-1447
pubmed: 32614136
J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):121-129
pubmed: 36428087
Sci Rep. 2017 Sep 6;7(1):10655
pubmed: 28878311